We are live on
!
Find out more
CASI
CASI Pharmaceuticals
CASI
CASI
Delisted
CASI was delisted on the 25th of February, 2026.
19 hedge funds and large institutions have $1.12M invested in CASI Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
3.6% less ownership
Funds ownership: 6.98% → 3.38% (-3.6%)
10% less funds holding
Funds holding: 21 → 19 (-2)
48% less capital invested
Capital invested by funds: $2.15M → $1.12M (-$1.03M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Holders
19
Holders Change
-2
Holders Change %
-9.52%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
8
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Jane Street
New York
|
+$75.7K |
| 2 |
Renaissance Technologies
New York
|
+$5.38K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.77K |
| 4 |
FA
Fiduciary Alliance
Greenville,
South Carolina
|
+$81 |
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$474K |
| 2 |
BlackRock
New York
|
-$245K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$204K |
| 4 |
WSC
Wellington Shields & Co
New York
|
-$143K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$88.2K |
